Onconova to Present at the Spring 2021 Oncology Investor Conference

NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will present a Company overview and hold one-on-one meetings during the Spring 2021 Oncology Investor Conference, sponsored by the National Foundation for Cancer Research.

Event: Spring 2021 Oncology Investor ConferenceDate: The virtual conference will take place March 29 to April 2, 2021Onconova Presentation: Thursday, April 1, 2021 at 11:50 a.m. Eastern timeConference Registration Link: https://www.oncologyinvestorconference.com/register

A webcast of Dr. Fruchtman’s presentation will be available on the Company’s website at https://investor.onconova.com/events-and-presentations beginning Friday, April 2nd.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, Onconova continues to conduct preclinical work investigating rigosertib in COVID-19. For more information, please visit www.onconova.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including patient enrollment timelines and indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:Avi OlerOnconova Therapeutics, Inc.267-759-3680 [email protected]https://www.onconova.com/contact/

Investor Contact:LHA Investor Relations Kim Sutton Golodetz212-838-3777[email protected]

Source: Onconova Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Hennessey Starts Production of Limited Edition 850 Horsepower Cadillac Escalade-V
• /C O R R E C T I O N -- MYCOM OSI/
• vLex Launches Vastly Expanded Vincent Legal GenAI Toolset, and AI-Focused Co-Development Lab